View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEvolva Holding 将来の成長Future 基準チェック /06現在、 Evolva Holdingの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長39.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024お知らせ • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.お知らせ • Feb 02Evolva Holding SA ADR - Sponsored to Be Deleted from OTC EquityEvolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated.お知らせ • Dec 29Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss ExchangeLallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange.お知らせ • Nov 23Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed.New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years).New Risk • Nov 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m).New Risk • Sep 28New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m).New Risk • Sep 13New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF11.0m market cap, or US$12.4m).お知らせ • Sep 07Evolva Receives Approval for Veri-Te Resveratrol in ThailandEvolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region.お知らせ • Jul 25Evolva Receives FDA Approval for Veri-teTM Resveratrol in TaiwanEvolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region.Board Change • Jun 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Andreas Pfluger was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 10Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)Full year 2022 results: CHF0.04 loss per share. Revenue: CHF15.5m (up 57% from FY 2021). Net loss: CHF43.4m (loss widened 5.1% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 27First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)First half 2022 results: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021). Revenue: CHF8.13m (up 28% from 1H 2021). Net loss: CHF28.9m (loss widened 14% from 1H 2021). Over the next year, revenue is forecast to grow 67% compared to a 21% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 21% per year.お知らせ • Aug 25Evolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023Evolva Holding SA announced that they will report fiscal year 2022 results on Mar 09, 2023Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Mar 12Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CHF0.05 loss per share (down from CHF0.038 loss in FY 2020). Revenue: CHF9.88m (up 31% from FY 2020). Net loss: CHF41.3m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 140% compared to a 12% decline forecast for the industry in the United Kingdom.Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Reported Earnings • Aug 29First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF6.38m (up 61% from 1H 2020). Net loss: CHF25.4m (loss widened 88% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.Executive Departure • Mar 10Chief Financial Officer has left the companyOn the 2nd of March, Andre Pennartz's tenure as Chief Financial Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Andre's name. A total of 3 executives have left over the last 12 months.Reported Earnings • Mar 02Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)Full year 2020 results: Net loss: CHF29.9m (loss widened 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 02Revenue misses expectationsRevenue missed analyst estimates by 28%. Over the next year, revenue is forecast to grow 124% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Is New 90 Day High Low • Jan 21New 90-day high: CHF0.25The company is up 13% from its price of CHF0.22 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 13% over the same period.Is New 90 Day High Low • Dec 08New 90-day high: CHF0.26The company is up 12% from its price of CHF0.24 on 08 September 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 27New 90-day low: CHF0.21The company is down 18% from its price of CHF0.26 on 29 July 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 03New 90-day low: CHF0.23The company is down 19% from its price of CHF0.28 on 02 July 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Evolva Holding は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測LSE:0QQJ - アナリストの将来予測と過去の財務データ ( )CHF Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20234-101-3-3N/A9/30/20238-98-8-6N/A6/30/202312-94-12-9N/A3/31/202314-69-17-14N/A12/31/202216-43-21-19N/A9/30/202214-44-27-24N/A6/30/202212-45-32-30N/A3/31/202211-43-33-30N/A12/31/202110-41-34-30N/A9/30/202110-41-32-27N/A6/30/202110-42-31-24N/A3/31/20219-36-30-24N/A12/31/20208-30-29-23N/A9/30/20208-27-24-19N/A6/30/20209-25-19-15N/A3/31/202010-23-19-13N/A12/31/201912-22-20-11N/A9/30/201912-23-24-15N/A6/30/201911-25-29-18N/A3/31/201910-27-33-21N/A12/31/20189-29-37-24N/A9/30/20188-31-39-29N/A6/30/20187-33-42-34N/A3/31/20187-36-39-35N/A12/31/20177-39-36-36N/A9/30/20178-38N/A-35N/A6/30/201710-37N/A-34N/A3/31/201710-37N/A-34N/A12/31/201610-36N/A-34N/A9/30/20169-35N/A-33N/A6/30/20169-34N/A-33N/A3/31/201611-33N/A-32N/A12/31/201513-32N/A-32N/A9/30/201514-30N/A-28N/A6/30/201514-28N/A-25N/A3/31/201512-25N/A-23N/A12/31/201411-21N/A-20N/A9/30/201410-19N/A-17N/A6/30/201410-18N/A-15N/A3/31/20149-17N/A-14N/A12/31/20139-16N/A-13N/A9/30/20138-15N/A-12N/A6/30/20137-14N/A-12N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0QQJの予測収益成長が 貯蓄率 ( 1.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 0QQJの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 0QQJの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 0QQJの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 0QQJの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0QQJの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/26 19:36終値2024/04/26 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Evolva Holding SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Sebastian BrayBerenbergSara WelfordEdison Investment ResearchMartin VoegtliResearch Partners AG1 その他のアナリストを表示
Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
お知らせ • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024
お知らせ • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.
お知らせ • Feb 02Evolva Holding SA ADR - Sponsored to Be Deleted from OTC EquityEvolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated.
お知らせ • Dec 29Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss ExchangeLallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange.
お知らせ • Nov 23Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed.
New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years).
New Risk • Nov 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m).
New Risk • Sep 28New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m).
New Risk • Sep 13New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF11.0m market cap, or US$12.4m).
お知らせ • Sep 07Evolva Receives Approval for Veri-Te Resveratrol in ThailandEvolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region.
お知らせ • Jul 25Evolva Receives FDA Approval for Veri-teTM Resveratrol in TaiwanEvolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region.
Board Change • Jun 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Andreas Pfluger was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 10Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)Full year 2022 results: CHF0.04 loss per share. Revenue: CHF15.5m (up 57% from FY 2021). Net loss: CHF43.4m (loss widened 5.1% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 27First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)First half 2022 results: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021). Revenue: CHF8.13m (up 28% from 1H 2021). Net loss: CHF28.9m (loss widened 14% from 1H 2021). Over the next year, revenue is forecast to grow 67% compared to a 21% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 21% per year.
お知らせ • Aug 25Evolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023Evolva Holding SA announced that they will report fiscal year 2022 results on Mar 09, 2023
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Mar 12Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CHF0.05 loss per share (down from CHF0.038 loss in FY 2020). Revenue: CHF9.88m (up 31% from FY 2020). Net loss: CHF41.3m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 140% compared to a 12% decline forecast for the industry in the United Kingdom.
Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Reported Earnings • Aug 29First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF6.38m (up 61% from 1H 2020). Net loss: CHF25.4m (loss widened 88% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.
Executive Departure • Mar 10Chief Financial Officer has left the companyOn the 2nd of March, Andre Pennartz's tenure as Chief Financial Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Andre's name. A total of 3 executives have left over the last 12 months.
Reported Earnings • Mar 02Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)Full year 2020 results: Net loss: CHF29.9m (loss widened 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 02Revenue misses expectationsRevenue missed analyst estimates by 28%. Over the next year, revenue is forecast to grow 124% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Is New 90 Day High Low • Jan 21New 90-day high: CHF0.25The company is up 13% from its price of CHF0.22 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 13% over the same period.
Is New 90 Day High Low • Dec 08New 90-day high: CHF0.26The company is up 12% from its price of CHF0.24 on 08 September 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 27New 90-day low: CHF0.21The company is down 18% from its price of CHF0.26 on 29 July 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 03New 90-day low: CHF0.23The company is down 19% from its price of CHF0.28 on 02 July 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.